Latest Advances in Lung Cancer Research

Mirati’s adagrasib and Keytruda show promise for KRAS G12C-mutated NSCLC with a 49% tumor shrinkage in trials.

Lung cancer screening saves lives. So why so do many at high risk not get one? Only 5.8% of people eligible for a free, low-dose CT scan actually get screened.

A new phase I/II clinical trial shows that repotrectinib had anti tumor activity in participants with the ROS-1-gene.

GSK’s TIM-3 lung cancer drug is moving into a pivotal trial after hitting the mark in the midphase portion of the study.

After results from a phase 2 trial, the FDA granted fast track designation to sapanisertib for patients with certain non–small cell lung cancer.

Scientists discover how air pollution triggers lung cancer in non-smokers, identifying a pathway where tiny PM2.5 particles “wake up” dormant cancer cells, leading to new prevention and treatment opportunities.

Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.

Scientists uncover link between car fumes and lung cancer that helps explain why so many non-smokers develop disease.

AstraZeneca and Daiichi Sankyo’s Enhertu scored an accelerated FDA approval in patients with HER2-mutant NSCLC.

Study shows that smoking cessation was associated with a nearly 30% improvement in overall survival with lung cancer patients.

In SAVANNAH Phase II trial, Tagrisso + savolitinib showed a 49% objective response rate in lung cancer patients with certain MET biomarkers.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.